Cailin Conner

DocwireNews

A multicenter, 2-year, randomized crossover trial in the <a href="https://journals.sagepub.com/doi/10.1177/19322968231197423" target="_blank" rel="noopener">Journal of Diabetes Science and Technology</a>&nbsp;compared the effects of 2 long-acting insulin formulations&mdash;insulin degludec (IDeg) and insulin glargine U100 (IGlar-100)&mdash;in patients with type 1 diabetes (T1D) who experienced recurrent nocturnal severe hypoglycemia. Specifically, the study aimed to evaluate continuous glucose monitoring (CGM)-recorded metrics to determine which insulin formulation offered better nocturnal glucose control while minimizing hypoglycemic episodes.Investigators enrolled 149 patients with T1D who had experienced at least 1 episode of nocturnal severe hypoglycemia within the past 2 years. Patients were randomized 1:1 to receive IDeg or IGlar-100. Patients were given the option of undergoing 6 days of blinded CGM monitoring twice during each treatment phase. The CGM data was analyzed for several key metrics, including the percentage of time spent within the target glucose range (TIR), time spent below the target range (TBR), time spent above the target range (TAR), and the coefficient of variation (CV).Out of the 149 participants initially enrolled, 74 were included in the final analysis. The differences in glucose control between the 2 treatments were most pronounced during the night (from 11:00 pm to 6:59 am).Patients receiving IGlar-100 achieved a TIR of 54.0%, whereas those using IDeg achieved a TIR of 49.0%, resulting in an estimated treatment difference (ETD) of &#8210;4.6%, signifying that IDeg resulted in a slightly decreased TIR, with statistical significance (P=.049).For 2 distinct hypoglycemic levels (level 1, 54-69 mg/dL; level 2, &lt;54 mg/dL), IDeg demonstrated reduced TBR compared with IGlar-100, with an ETD of &#8210;1.7% (P&lt;.05) for level 1 and &#8210;1.3% (P=.001) for level 2. IDeg led to elevated TAR at 2 hyperglycemic levels (level 1, 181-250 mg/dL; level 2, &gt;250 mg/dL) compared with IGlar-100, with an ETD of 4% for both levels (P&lt;.05 for both). The mean CV was lower with IDeg than with IGlar-100, showing an ETD of &#8210;3.4% (P&lt;.05), indicating that IDeg provided more consistent and predictable glucose levels.According to the investigators, &ldquo;For people with T1D suffering from recurrent nocturnal severe hypoglycemia, treatment with IDeg, compared with IGlar-100, results in a lower TBR and CV during the night at the expense of more TAR.&rdquo;&nbsp;

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Insulin Degludec Offers Better Stability Than Insulin Glargine U100 in This Patient Population

Diabetes

A randomized trial found that insulin degludec offered lower nocturnal hypoglycemia risk and better glucose stability at the expense of slightly reduced time.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe